

Figure 1




Figure 2





FIGURE 3



662780" 453400




FIGURE 4(a)





FIGURE 4(b)

FIGURE 5






FIGURE 6(a)




FIGURE 6(b)

662780" 11554600

FIGURE 7






FIGURE 8A



662F80"TF534660

FIGURE 8B






FIGURE 9

% of Control (Mean \pm S.E.)






FIGURE 10A



00376544 001799

Cells/well (Mean \pm S.E.) ($\times 10^{-4}$)






FIGURE 10B

Effects of MP/PO chiral oligos on DOHH2 cell growth




FIGURE 11

Effects of MP/POchimer. oligos
on MCF7 breast carcinoma cell line.




FIGURE 12




FIGURE 13

As72
5'-AGCGCGGCGCGGCAGCGC-3'
Sc72
5'-GGGCGGGAAGGGCGCGCGC-3'

As23
5'-GCGCGGCGGCGGCGGCA-3'
Sc23
5'-GGGCGGAGCGCGCGCGCGG-3'

As-18' mer
5'-TCTCCAGCGTGCGCCAT-3'
Sc-18' mer
5'-TGCACCTACCGCTCGGCCT-3'